查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1276888

非何杰金氏淋巴瘤诊断的全球市场:产业趋势与预测(～2030年)

Global Non-Hodgkin Lymphoma Diagnostics Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 752 Pages | 商品交期: 请询问到货日

价格

全球非何杰金氏淋巴瘤诊断的市场规模在2023年～2030年的预测期间将记录8.5％相当的年复合成长率。

非何杰金氏淋巴瘤的盛行率增加，非何杰金氏淋巴瘤诊断的人工智能的进步等，是全球非何杰金氏淋巴瘤诊断市场主要成长促进因素。

本报告提供全球非何杰金氏淋巴瘤诊断市场相关调查分析，提供市场概要，各市场区隔·各地区的市场分析，竞争分析，企业简介等系统性资讯。

目录

第1章 简介

第2章 市场明细

第3章 摘要整理

第4章 重要考察

  • PESTEL分析
  • 波特的五力分析

第5章 产业考察

第6章 全球非何杰金氏淋巴瘤诊断市场:法规

第7章 市场概要

  • 促进因素
  • 阻碍因素
  • 机会
  • 课题

第8章 全球非何杰金氏淋巴瘤诊断市场:检验各类型

  • 概要
  • 影像诊断
  • 切片检查
  • 免疫组织化学
  • 生物标记试验
  • 遗传基因检验
  • 细胞遗传学
  • 腰椎穿刺(脊椎穿刺)
  • 血液检验
  • 细胞化学
  • 其他

第9章 全球非何杰金氏淋巴瘤诊断市场:肿瘤各类型

  • 概要
  • 进行性淋巴瘤
  • 缓恶性淋巴肿瘤

第10章 全球非何杰金氏淋巴瘤诊断市场:各用途

  • 概要
  • 筛检
  • 诊断·预测
  • 预后
  • 研究

第11章 全球非何杰金氏淋巴瘤诊断市场:癌症各阶段

  • 概要
  • 阶段IV
  • 阶段I
  • 阶段III
  • 阶段II
  • 阶段0

第12章 全球非何杰金氏淋巴瘤诊断市场:各技术

  • 概要
  • 萤光原位杂合反应
  • 下一代序列
  • 氟免疫化验
  • 比较基因杂合反应
  • 免疫组织化学
  • 其他

第13章 全球非何杰金氏淋巴瘤诊断市场:各产品

  • 概要
  • 设备为基础的产品
  • 平台为基础的产品
  • 套件·试剂
  • 其他的消耗品

第14章 全球非何杰金氏淋巴瘤诊断市场:各终端用户

  • 概要
  • 医院
  • 诊断中心
  • 癌症研究中心
  • 学术机构
  • 门诊病人手术中心
  • 其他

第15章 全球非何杰金氏淋巴瘤诊断市场:各流通管道

  • 概要
  • 直接竞标
  • 零售
  • 其他

第16章 全球非何杰金氏淋巴瘤诊断市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 荷兰
    • 瑞士
    • 比利时
    • 土耳其
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 印尼
    • 菲律宾
    • 泰国
    • 马来西亚
    • 越南
    • 新加坡
    • 其他亚太地区
  • 中东·非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 埃及
    • 以色列
    • 其他中东·非洲
  • 南美
    • 巴西
    • 阿根廷
    • 其他南美

第17章 全球非何杰金氏淋巴瘤诊断市场:企业形势

  • 企业占有率分析:世界
  • 企业占有率分析:北美
  • 企业占有率分析:欧洲
  • 企业占有率分析:亚太地区

第18章 SWOT分析

第19章 全球非何杰金氏淋巴瘤诊断市场

The global Non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 8.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Non-Hodgkin Lymphoma Diagnostics Market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa)Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global non-Hodgkin lymphoma diagnostics market are:

Increased growth in the prevalence of Non-Hodgkin Lymphoma

Advancement in artificial intelligence in the diagnosis of non-Hodgkin lymphoma

Market Players:

Some of the major players operating in the global non-Hodgkin lymphoma diagnostics market are:

CANON MEDICAL SYSTEMS CORPORATION

Koninklijke Philips N.V.

Siemens Healthcare GmbH

Danaher.

Bio-Rad Laboratories, Inc.

General Electric Company

Sysmex Corporation

Grail

F. Hoffmann-La Roche

Neusoft Corporation

Agilent Technologies, Inc.

NeoGenomics Laboratories

Hologic, Inc

Integrated DNA Technologies, Inc.

CENTOGENE N.V.

Merit Medical Systems

Invitae Corporation

PerkinElmer Inc.

QIAGEN

GeneDx, LLC

TABLE OF CONTENTS

1 INTRODUCTION 84

  • 1.1 OBJECTIVES OF THE STUDY 84
  • 1.2 MARKET DEFINITION 84
  • 1.3 OVERVIEW OF THE GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 84
  • 1.4 LIMITATIONS 86
  • 1.5 MARKETS COVERED 87

2 MARKET SEGMENTATION 90

  • 2.1 MARKETS COVERED 90
  • 2.2 GEOGRAPHICAL SCOPE 91
  • 2.3 YEARS CONSIDERED FOR THE STUDY 92
  • 2.4 CURRENCY AND PRICING 92
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 93
  • 2.6 MULTIVARIATE MODELLING 96
  • 2.7 PRODUCT TYPE LIFELINE CURVE 96
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
  • 2.9 DBMR MARKET POSITION GRID 98
  • 2.10 MARKET APPLICATION COVERAGE GRID 99
  • 2.11 VENDOR SHARE ANALYSIS 100
  • 2.12 SECONDARY SOURCES 101
  • 2.13 ASSUMPTIONS 101

3 EXECUTIVE SUMMARY 102

4 PREMIUM INSIGHTS 106

  • 4.1 PESTEL ANALYSIS 108
  • 4.2 PORTER'S 5 FORCES 109

5 INDUSTRY INSIGHTS 110

6 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 111

7 MARKET OVERVIEW 113

  • 7.1 DRIVERS 115
    • 7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 115
    • 7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 115
    • 7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 115
    • 7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 116
  • 7.2 RESTRAINTS 116
    • 7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 116
    • 7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 117
  • 7.3 OPPORTUNITIES 118
    • 7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 118
    • 7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 118
    • 7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 118
  • 7.4 CHALLENGES 119
    • 7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 119
    • 7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 119
    • 7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 120

8 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 121

  • 8.1 OVERVIEW 122
  • 8.2 IMAGING 125
    • 8.2.1 COMPUTED TOMOGRAPHY (CT) 126
    • 8.2.2 CHEST X-RAY 126
    • 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 126
    • 8.2.4 ULTRASOUND 126
    • 8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 126
  • 8.3 BIOPSY 126
    • 8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 127
    • 8.3.2 CORE NEEDLE BIOPSY 127
  • 8.4 IMMUNOHISTOCHEMISTRY 127
  • 8.5 BIOMARKER TEST 128
    • 8.5.1 BETA 2-M 129
    • 8.5.2 LDH 129
    • 8.5.3 CA-125 129
    • 8.5.4 TP53 129
    • 8.5.5 NPM1 130
    • 8.5.6 OTHERS 130
  • 8.6 GENETIC TEST 130
  • 8.7 CYTOGENETICS 130
  • 8.8 LUMBAR PUNCTURE (SPINAL TAP) 131
  • 8.9 BLOOD TEST 132
  • 8.10 CYTOCHEMISTRY 132
  • 8.11 OTHERS 133

9 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 134

  • 9.1 OVERVIEW 135
  • 9.2 AGGRESSIVE LYMPHOMAS 137
    • 9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 138
      • 9.2.1.1 INSTRUMENT BASED PRODUCTS 139
      • 9.2.1.2 PLATFORM BASED PRODUCTS 139
      • 9.2.1.3 KITS AND REAGENTS 139
      • 9.2.1.4 OTHER CONSUMABLES 139
    • 9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 139
      • 9.2.2.1 INSTRUMENT BASED PRODUCTS 140
      • 9.2.2.2 PLATFORM BASED PRODUCTS 140
      • 9.2.2.3 KITS AND REAGENTS 140
      • 9.2.2.4 OTHER CONSUMABLES 140
    • 9.2.3 MANTLE CELL LYMPHOMA 140
      • 9.2.3.1 INSTRUMENT BASED PRODUCTS 141
      • 9.2.3.2 PLATFORM BASED PRODUCTS 141
      • 9.2.3.3 KITS AND REAGENTS 141
      • 9.2.3.4 OTHER CONSUMABLES 141
    • 9.2.4 PERIPHERAL T-CELL LYMPHOMA 141
      • 9.2.4.1 INSTRUMENT BASED PRODUCTS 142
      • 9.2.4.2 PLATFORM BASED PRODUCTS 142
      • 9.2.4.3 KITS AND REAGENTS 142
      • 9.2.4.4 OTHER CONSUMABLES 142
    • 9.2.5 LYMPHOBLASTIC LYMPHOMA 142
      • 9.2.5.1 INSTRUMENT BASED PRODUCTS 143
      • 9.2.5.2 PLATFORM BASED PRODUCTS 143
      • 9.2.5.3 KITS AND REAGENTS 143
      • 9.2.5.4 OTHER CONSUMABLES 143
    • 9.2.6 BURKITT LYMPHOMA 143
      • 9.2.6.1 INSTRUMENT BASED PRODUCTS 144
      • 9.2.6.2 PLATFORM BASED PRODUCTS 144
      • 9.2.6.3 KITS AND REAGENTS 144
      • 9.2.6.4 OTHER CONSUMABLES 144
  • 9.3 INDOLENT LYMPHOMAS 144
    • 9.3.1 FOLLICULAR LYMPHOMA 145
      • 9.3.1.1 INSTRUMENT BASED PRODUCTS 146
      • 9.3.1.2 PLATFORM BASED PRODUCTS 146
      • 9.3.1.3 KITS AND REAGENTS 146
      • 9.3.1.4 OTHER CONSUMABLES 146
    • 9.3.2 CUTANEOUS T-CELL LYMPHOMA 146
      • 9.3.2.1 INSTRUMENT BASED PRODUCTS 147
      • 9.3.2.2 PLATFORM BASED PRODUCTS 147
      • 9.3.2.3 KITS AND REAGENTS 147
      • 9.3.2.4 OTHER CONSUMABLES 147
    • 9.3.3 MARGINAL ZONE B CELL LYMPHOMA 147
      • 9.3.3.1 INSTRUMENT BASED PRODUCTS 148
      • 9.3.3.2 PLATFORM BASED PRODUCTS 148
      • 9.3.3.3 KITS AND REAGENTS 148
      • 9.3.3.4 OTHER CONSUMABLES 148
    • 9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 148
      • 9.3.4.1 INSTRUMENT BASED PRODUCTS 149
      • 9.3.4.2 PLATFORM BASED PRODUCTS 149
      • 9.3.4.3 KITS AND REAGENTS 149
      • 9.3.4.4 OTHER CONSUMABLES 149
    • 9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 149
      • 9.3.5.1 INSTRUMENT BASED PRODUCTS 150
      • 9.3.5.2 PLATFORM BASED PRODUCTS 150
      • 9.3.5.3 KITS AND REAGENTS 150
      • 9.3.5.4 OTHER CONSUMABLES 150

10 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 151

  • 10.1 OVERVIEW 152
  • 10.2 SCREENING 154
    • 10.2.1 INSTRUMENT BASED PRODUCTS 155
    • 10.2.2 PLATFORM BASED PRODUCTS 155
    • 10.2.3 KITS AND REAGENTS 156
    • 10.2.4 OTHER CONSUMABLES 156
  • 10.3 DIAGNOSTIC AND PREDICTIVE 156
    • 10.3.1 INSTRUMENT BASED PRODUCTS 157
    • 10.3.2 PLATFORM BASED PRODUCTS 157
    • 10.3.3 KITS AND REAGENTS 157
    • 10.3.4 OTHER CONSUMABLES 157
  • 10.4 PROGNOSTIC 157
    • 10.4.1 INSTRUMENT BASED PRODUCTS 158
    • 10.4.2 PLATFORM BASED PRODUCTS 158
    • 10.4.3 KITS AND REAGENTS 158
    • 10.4.4 OTHER CONSUMABLES 159
  • 10.5 RESEARCH 159
    • 10.5.1 INSTRUMENT BASED PRODUCTS 160
    • 10.5.2 PLATFORM BASED PRODUCTS 160
    • 10.5.3 KITS AND REAGENTS 160
    • 10.5.4 OTHER CONSUMABLES 160

11 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 161

  • 11.1 OVERVIEW 162
  • 11.2 STAGE IV 164
  • 11.3 STAGE I 165
  • 11.4 STAGE III 166
  • 11.5 STAGE II 167
  • 11.6 STAGE 0 168

12 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 169

  • 12.1 OVERVIEW 170
  • 12.2 FLUORESCENT IN SITU HYBRIDIZATION 172
  • 12.3 NEXT GENERATION SEQUENCING 173
  • 12.4 FLUORIMMUNOASSAY 174
  • 12.5 COMPARATIVE GENOMIC HYBRIDIZATION 175
  • 12.6 IMMUNOHISTOLOCHEMICAL 175
  • 12.7 OTHER 176

13 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 177

  • 13.1 OVERVIEW 178
  • 13.2 INSTRUMENT BASED PRODUCTS 180
    • 13.2.1 IMAGING 181
    • 13.2.2 BIOPSY 181
  • 13.3 PLATFORM BASED PRODUCTS 182
    • 13.3.1 NEXT-GENERATION SEQUENCING 183
    • 13.3.2 MICROARRAYS 183
    • 13.3.3 PCR 183
    • 13.3.4 OTHERS 183
  • 13.4 KITS AND REAGENTS 183
    • 13.4.1 NON-HODGKIN LYMPHOMA PANELS 184
    • 13.4.2 IMMUNOHISTOCHEMISTRY STAINS 184
    • 13.4.3 OTHERS 184
  • 13.5 OTHER CONSUMABLES 185

14 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 186

  • 14.1 OVERVIEW 187
  • 14.2 HOSPITALS 189
  • 14.3 DIAGNOSTIC CENTERS 190
  • 14.4 CANCER RESEARCH CENTERS 191
  • 14.5 ACADEMIC INSTITUTES 192
  • 14.6 AMBULATORY SURGICAL CENTERS 192
  • 14.7 OTHERS 193

15 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 194

  • 15.1 OVERVIEW 195
  • 15.2 DIRECT TENDER 197
  • 15.3 RETAIL SALES 198
  • 15.4 OTHERS 199

16 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 200

  • 16.1 OVERVIEW 201
  • 16.2 NORTH AMERICA 207
    • 16.2.1 U.S. 225
    • 16.2.2 CANADA 237
    • 16.2.3 MEXICO 249
  • 16.3 EUROPE 261
    • 16.3.1 GERMANY 280
    • 16.3.2 UNITED KINGDOM 292
    • 16.3.3 FRANCE 304
    • 16.3.4 ITALY 316
    • 16.3.5 SPAIN 328
    • 16.3.6 RUSSIA 340
    • 16.3.7 NETHERLANDS 352
    • 16.3.8 SWITZERLAND 364
    • 16.3.9 BELGIUM 376
    • 16.3.10 TURKEY 388
    • 16.3.11 REST OF EUROPE 400
  • 16.4 ASIA-PACIFIC 401
    • 16.4.1 CHINA 421
    • 16.4.2 JAPAN 435
    • 16.4.3 INDIA 449
    • 16.4.4 AUSTRALIA 463
    • 16.4.5 SOUTH KOREA 477
    • 16.4.6 INDONESIA 491
    • 16.4.7 PHILIPPINES 505
    • 16.4.8 THAILAND 519
    • 16.4.9 MALAYSIA 533
    • 16.4.10 VIETNAM 547
    • 16.4.11 SINGAPORE 560
    • 16.4.12 REST OF ASIA-PACIFIC 574
  • 16.5 MIDDLE EAST AND AFRICA 575
    • 16.5.1 SOUTH AFRICA 593
    • 16.5.2 SAUDI ARABIA 606
    • 16.5.3 U.A.E. 619
    • 16.5.4 EGYPT 632
    • 16.5.5 ISRAEL 646
    • 16.5.6 REST OF MIDDLE EAST AND AFRICA 660
  • 16.6 SOUTH AMERICA 661
    • 16.6.1 BRAZIL 680
    • 16.6.2 ARGENTINA 694
    • 16.6.3 REST OF SOUTH AMERICA 707

17 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 708

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL 708
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 709
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE 710
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 711

18 SWOT ANALYSIS 712

19 GLOBAL NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 713

  • 19.1 CANON MEDICAL SYSTEMS CORPORATION 713
    • 19.1.1 COMPANY SNAPSHOT 713
    • 19.1.2 REVENUE ANALYSIS 713
    • 19.1.3 COMPANY SHARE ANALYSIS 714
    • 19.1.4 PRODUCT PORTFOLIO 714
    • 19.1.5 RECENT DEVELOPMENT 714
  • 19.2 KONINKLIJKE PHILIPS N.V. 715
    • 19.2.1 COMPANY SNAPSHOT 715
    • 19.2.2 REVENUE ANALYSIS 715
    • 19.2.3 COMPANY SHARE ANALYSIS 716
    • 19.2.4 PRODUCT PORTFOLIO 716
    • 19.2.5 RECENT DEVELOPMENTS 716
  • 19.3 SIEMENS HEALTHCARE GMBH 717
    • 19.3.1 COMPANY SNAPSHOT 717
    • 19.3.2 REVENUE ANALYSIS 717
    • 19.3.3 COMPANY SHARE ANALYSIS 718
    • 19.3.4 PRODUCT PORTFOLIO 718
    • 19.3.5 RECENT DEVELOPMENT 719
  • 19.4 DANAHER. 720
    • 19.4.1 COMPANY SNAPSHOT 720
    • 19.4.2 REVENUE ANALYSIS 720
    • 19.4.3 COMPANY SHARE ANALYSIS 721
    • 19.4.4 PRODUCT PORTFOLIO 721
    • 19.4.5 RECENT DEVELOPMENTS 722
  • 19.5 BIO-RAD LABORATORIES, INC. 723
    • 19.5.1 COMPANY SNAPSHOT 723
    • 19.5.2 REVENUE ANALYSIS 723
    • 19.5.3 COMPANY SHARE ANALYSIS 724
    • 19.5.4 PRODUCT PORTFOLIO 724
    • 19.5.5 RECENT DEVELOPMENT 724
  • 19.6 AGILENT TECHNOLOGIES, INC. 725
    • 19.6.1 COMPANY PROFILE 725
    • 19.6.2 REVENUE ANALYSIS 725
    • 19.6.3 PRODUCT PORTFOLIO 726
    • 19.6.4 RECENT DEVELOPMENT 726
  • 19.7 CENTOGENE N.V. 727
    • 19.7.1 COMPANY SNAPSHOT 727
    • 19.7.2 PRODUCT PORTFOLIO 727
    • 19.7.3 RECENT DEVELOPMENT 727
  • 19.8 F. HOFFMANN- LA ROCHE LTD 728
    • 19.8.1 COMPANY SNAPSHOT 728
    • 19.8.2 REVENUE ANALYSIS 728
    • 19.8.3 PRODUCT PORTFOLIO 729
    • 19.8.4 RECENT DEVELOPMENTS 729
  • 19.9 GENERAL ELECTRIC COMPANY 730
    • 19.9.1 COMPANY SNAPSHOT 730
    • 19.9.2 REVENUE ANALYSIS 730
    • 19.9.3 PRODUCT PORTFOLIO 731
    • 19.9.4 RECENT DEVELOPMENTS 731
  • 19.10 GENEDX, LLC 732
    • 19.10.1 COMPANY SNAPSHOT 732
    • 19.10.2 PRODUCT PORTFOLIO 732
    • 19.10.3 RECENT DEVELOPMENT 732
  • 19.11 GRAIL 733
    • 19.11.1 COMPANY PROFILE 733
    • 19.11.2 PRODUCT PORTFOLIO 733
    • 19.11.3 RECENT DEVELOPMENT 733
  • 19.12 HOLOGIC INC. 734
    • 19.12.1 COMPANY SNAPSHOT 734
    • 19.12.2 REVENUE ANALYSIS 734
    • 19.12.3 PRODUCT PORTFOLIO 735
    • 19.12.4 RECENT DEVELOPMENT 735
  • 19.13 INVITAE CORPORATION 736
    • 19.13.1 COMPANY PROFILE 736
    • 19.13.2 REVENUE ANALYSIS 736
    • 19.13.3 PRODUCT PORTFOLIO 737
    • 19.13.4 RECENT DEVELOPMENT 737
  • 19.14 NEUSOFT CORPORATION 738
    • 19.14.1 COMPANY SNAPSHOT 738
    • 19.14.2 REVENUE ANALYSIS 738
    • 19.14.3 PRODUCT PORTFOLIO 739
    • 19.14.4 RECENT DEVELOPMENT 739
  • 19.15 NEOGENOMICS LABORATORIES 740
    • 19.15.1 COMPANY SNAPSHOT 740
    • 19.15.2 REVENUE ANALYSIS 740
    • 19.15.3 PRODUCT PORTFOLIO 741
    • 19.15.4 RECENT DEVELOPMENTS 741
  • 19.16 PERKINELMER INC 742
    • 19.16.1 COMPANY PROFILE 742
    • 19.16.2 REVENUE ANALYSIS 742
    • 19.16.3 PRODUCT PORTFOLIO 743
    • 19.16.4 RECENT DEVELOPMENT 743
  • 19.17 QIAGEN 744
    • 19.17.1 COMPANY SNAPSHOT 744
    • 19.17.2 REVENUE ANALYSIS 744
    • 19.17.3 PRODUCT PORTFOLIO 745
    • 19.17.4 RECENT DEVELOPMENT 745
  • 19.18 SYSMEX CORPORATION 746
    • 19.18.1 COMPANY SNAPSHOT 746
    • 19.18.2 REVENUE ANALYSIS 746
    • 19.18.3 PRODUCT PORTFOLIO 747
    • 19.18.4 RECENT DEVELOPMENTS 747

20 QUESTIONNAIRE 748

21 RELATED REPORTS 752

LIST OF TABLES

  • TABLE 1 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 2 GLOBAL IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 3 GLOBAL IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 4 GLOBAL BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 5 GLOBAL BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 6 GLOBAL IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
  • TABLE 7 GLOBAL BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
  • TABLE 8 GLOBAL BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 9 GLOBAL GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 130
  • TABLE 10 GLOBAL CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
  • TABLE 11 GLOBAL LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
  • TABLE 12 GLOBAL BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 132
  • TABLE 13 GLOBAL CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
  • TABLE 14 GLOBAL OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
  • TABLE 15 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 16 GLOBAL AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
  • TABLE 17 GLOBAL AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 18 GLOBAL DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 139
  • TABLE 19 GLOBAL ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 140
  • TABLE 20 GLOBAL MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 141
  • TABLE 21 GLOBAL PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 142
  • TABLE 22 GLOBAL LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 143
  • TABLE 23 GLOBAL BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 144
  • TABLE 24 GLOBAL INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
  • TABLE 25 GLOBAL AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 26 GLOBAL FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 146
  • TABLE 27 GLOBAL CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 147
  • TABLE 28 GLOBAL MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 148
  • TABLE 29 GLOBAL LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 149
  • TABLE 30 GLOBAL SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 150
  • TABLE 31 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 154
  • TABLE 32 GLOBAL SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 155
  • TABLE 33 GLOBAL SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 155
  • TABLE 34 GLOBAL DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 156
  • TABLE 35 GLOBAL DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 157
  • TABLE 36 GLOBAL PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 158
  • TABLE 37 GLOBAL PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 158
  • TABLE 38 GLOBAL RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 159
  • TABLE 39 GLOBAL RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 160
  • TABLE 40 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 164
  • TABLE 41 GLOBAL STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 165
  • TABLE 42 GLOBAL STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 166
  • TABLE 43 GLOBAL STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 167
  • TABLE 44 GLOBAL STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION 167
  • TABLE 45 GLOBAL STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 168
  • TABLE 46 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 172
  • TABLE 47 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 173
  • TABLE 48 GLOBAL NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 174
  • TABLE 49 GLOBAL FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 174
  • TABLE 50 GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 175
  • TABLE 51 GLOBAL IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 176
  • TABLE 52 GLOBAL OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 176
  • TABLE 53 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
  • TABLE 54 GLOBAL INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 181
  • TABLE 55 GLOBAL INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 181
  • TABLE 56 GLOBAL PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 182
  • TABLE 57 GLOBAL PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 183
  • TABLE 58 GLOBAL KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 184
  • TABLE 59 GLOBAL INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 184
  • TABLE 60 GLOBAL OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)) 185
  • TABLE 61 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 189
  • TABLE 62 GLOBAL HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 190
  • TABLE 63 GLOBAL DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 191
  • TABLE 64 GLOBAL CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 191
  • TABLE 65 GLOBAL ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 192
  • TABLE 66 GLOBAL AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 193
  • TABLE 67 GLOBAL OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 193
  • TABLE 68 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 197
  • TABLE 69 GLOBAL DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 198
  • TABLE 70 GLOBAL RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 198
  • TABLE 71 GLOBAL OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 199
  • TABLE 72 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 206
  • TABLE 73 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 212
  • TABLE 74 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 212
  • TABLE 75 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 213
  • TABLE 76 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 213
  • TABLE 77 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 213
  • TABLE 78 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 214
  • TABLE 79 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 214
  • TABLE 80 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 214
  • TABLE 81 NORTH AMERICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 215
  • TABLE 82 NORTH AMERICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 215
  • TABLE 83 NORTH AMERICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 215
  • TABLE 84 NORTH AMERICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 216
  • TABLE 85 NORTH AMERICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 216
  • TABLE 86 NORTH AMERICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 216
  • TABLE 87 NORTH AMERICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 217
  • TABLE 88 NORTH AMERICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 217
  • TABLE 89 NORTH AMERICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 217
  • TABLE 90 NORTH AMERICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 218
  • TABLE 91 NORTH AMERICA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 218
  • TABLE 92 NORTH AMERICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 218
  • TABLE 93 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 219
  • TABLE 94 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 219
  • TABLE 95 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 219
  • TABLE 96 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 219
  • TABLE 97 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 220
  • TABLE 98 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 220
  • TABLE 99 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 220
  • TABLE 100 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 220
  • TABLE 101 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 221
  • TABLE 102 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 221
  • TABLE 103 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 221
  • TABLE 104 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 222
  • TABLE 105 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 222
  • TABLE 106 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 222
  • TABLE 107 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 223
  • TABLE 108 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 223
  • TABLE 109 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 223
  • TABLE 110 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 224
  • TABLE 111 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 225
  • TABLE 112 U.S. IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 225
  • TABLE 113 U.S. BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 226
  • TABLE 114 U.S. BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 226
  • TABLE 115 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 226
  • TABLE 116 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 227
  • TABLE 117 U.S. AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 227
  • TABLE 118 U.S. DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 227
  • TABLE 119 U.S. ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 228
  • TABLE 120 U.S. MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 228
  • TABLE 121 U.S. PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 228
  • TABLE 122 U.S. LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 229
  • TABLE 123 U.S. BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 229
  • TABLE 124 U.S. INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 229
  • TABLE 125 U.S. FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 230
  • TABLE 126 U.S. CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 230
  • TABLE 127 U.S. MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 230
  • TABLE 128 U.S. LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 231
  • TABLE 129 U.S. SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 231
  • TABLE 130 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 231
  • TABLE 131 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 232
  • TABLE 132 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 232
  • TABLE 133 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 232
  • TABLE 134 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 232
  • TABLE 135 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 233
  • TABLE 136 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 233
  • TABLE 137 U.S. KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 233
  • TABLE 138 U.S. KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 233
  • TABLE 139 U.S. KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 234
  • TABLE 140 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 234
  • TABLE 141 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 234
  • TABLE 142 U.S. SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 235

LIST OF FIGURES

  • FIGURE 1 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 90
  • FIGURE 2 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION 93
  • FIGURE 3 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS 94
  • FIGURE 4 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 95
  • FIGURE 5 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 95
  • FIGURE 6 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING 96
  • FIGURE 7 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 97
  • FIGURE 8 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 98
  • FIGURE 9 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 99
  • FIGURE 10 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 100
  • FIGURE 11 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 104
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE, AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN THE GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 105
  • FIGURE 13 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 106
  • FIGURE 14 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028 106
  • FIGURE 15 NORTH AMERICA IS THE FASTEST GROWING MARKET IN THE GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 107
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 114
  • FIGURE 17 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022 122
  • FIGURE 18 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 123
  • FIGURE 19 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 123
  • FIGURE 20 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 124
  • FIGURE 21 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022 135
  • FIGURE 22 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION) 136
  • FIGURE 23 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030) 136
  • FIGURE 24 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE 137
  • FIGURE 25 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022 152
  • FIGURE 26 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 153
  • FIGURE 27 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030) 153
  • FIGURE 28 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE 154
  • FIGURE 29 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022 162
  • FIGURE 30 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION) 163
  • FIGURE 31 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030) 163
  • FIGURE 32 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE 164
  • FIGURE 33 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022 170
  • FIGURE 34 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 171
  • FIGURE 35 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030) 171
  • FIGURE 36 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE 172
  • FIGURE 37 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022 178
  • FIGURE 38 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 179
  • FIGURE 39 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030) 179
  • FIGURE 40 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE 180
  • FIGURE 41 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022 187
  • FIGURE 42 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 188
  • FIGURE 43 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 188
  • FIGURE 44 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 189
  • FIGURE 45 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022 195
  • FIGURE 46 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 196
  • FIGURE 47 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 196
  • FIGURE 48 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 197
  • FIGURE 49 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 202
  • FIGURE 50 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY REGION (2022) 204
  • FIGURE 51 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 204
  • FIGURE 52 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 205
  • FIGURE 53 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030) 205
  • FIGURE 54 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 208
  • FIGURE 55 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022) 210
  • FIGURE 56 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 210
  • FIGURE 57 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 211
  • FIGURE 58 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 211
  • FIGURE 59 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 262
  • FIGURE 60 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022) 264
  • FIGURE 61 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 264
  • FIGURE 62 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 265
  • FIGURE 63 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 266
  • FIGURE 64 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 402
  • FIGURE 65 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022) 404
  • FIGURE 66 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 404
  • FIGURE 67 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 405
  • FIGURE 68 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 406
  • FIGURE 69 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 576
  • FIGURE 70 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022) 578
  • FIGURE 71 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 578
  • FIGURE 72 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 579
  • FIGURE 73 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 579
  • FIGURE 74 SOUTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 662
  • FIGURE 75 SOUTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022) 664
  • FIGURE 76 SOUTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 664
  • FIGURE 77 SOUTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 665
  • FIGURE 78 SOUTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 665
  • FIGURE 79 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 708
  • FIGURE 80 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 709
  • FIGURE 81 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022(%) 710
  • FIGURE 82 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 711